The Future of Surgery: The long path to market for surgical robots with Adam Sachs from Vicarious
Adam Sachs, co-founder and CEO of Vicarious Surgical, discusses the company's progress in developing a single-port surgical robot that operates through a 1.8 cm incision, detailing the transition from VR-based Beta 1 to a hybrid interface in Beta 2. He explains the rigorous FDA regulatory path, including electromagnetic compatibility testing against electro-surgery tools and the strategic decision to delay AI features to ensure traceability. The episode also covers Vicarious' public funding status, supply chain challenges, and the potential for remote training applications, alongside industry news on GM's Cruise and Amazon's iRobot acquisition.